Maximus (NYSE:MMS) Announces Earnings Results, Beats Expectations By $0.26 EPS

Maximus (NYSE:MMS – Get Free Report) released its earnings results on Thursday. The health services provider reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.26, Zacks reports. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.30 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%. Maximus’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.62 EPS. Maximus updated its FY 2027 guidance to 7.500-8.000 EPS.

Here are the key takeaways from Maximus’ conference call:

  • Fiscal 2026 adjusted EPS rose 12% to $8.24, while adjusted EBITDA margin expanded to 14.2% from 12.9%. Maximus attributed the improvement to automation, technology investments and disciplined execution.
  • The Agile Defense acquisition has closed, adding a defense and national security business that Maximus expects to generate roughly $450 million in calendar 2027 revenue and double-digit organic growth. Management sees the deal as a way to expand in a growing market, though integration and growth execution remain important.
  • Fiscal 2027 guidance calls for adjusted EPS of $7.50–$8.00 and an adjusted EBITDA margin of about 12.8%, both below fiscal 2026 results. The comparison is weighed down by the absence of VA medical-exam incentives in the forecast; excluding those prior-year incentives, management says the EPS midpoint implies about 8% growth.
  • Maximus expects fiscal 2027 free cash flow of $700–$800 million, supported by normalized collections and cash received after year-end; it had collected more than $330 million from a previously delayed customer by November 13. Fiscal 2026 free cash flow was just $69 million, largely because of collection timing.
  • Management expects mid-single-digit organic growth in U.S. Services, supported by Medicaid and SNAP work tied to OBBBA implementation, and reports that five states have contracted for related support. However, state implementation varies, and a new option to delay certain adverse Medicaid actions could affect timing and scope.

Maximus Trading Up 1.0%

Shares of MMS stock opened at $62.64 on Friday. The stock has a market capitalization of $3.28 billion, a PE ratio of 8.60 and a beta of 0.57. Maximus has a 1-year low of $51.04 and a 1-year high of $100.00. The business has a 50-day moving average of $60.19 and a 200 day moving average of $62.81. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.42 and a quick ratio of 2.42.

Maximus Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be paid a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Friday, November 13th. Maximus’s payout ratio is 19.50%.

Insider Transactions at Maximus

In related news, insider Michelle Link sold 3,208 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $54.23, for a total transaction of $173,969.84. Following the transaction, the insider directly owned 13,881 shares in the company, valued at $752,766.63. This trade represents a 18.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

MMS has been the topic of a number of recent research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Maximus in a research report on Friday, November 13th. Zacks Research upgraded shares of Maximus from a “strong sell” rating to a “hold” rating in a report on Thursday, October 1st. Finally, Wall Street Zen upgraded shares of Maximus from a “hold” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Hold rating. According to MarketBeat, Maximus has an average rating of “Hold”.

Get Our Latest Analysis on MMS

Key Stories Impacting Maximus

Investors following MMS have been watching these stories:

  • Positive Sentiment: Fiscal Q4 adjusted earnings were $2.11 per share, above consensus estimates of roughly $1.85–$1.88 and up from $1.62 a year earlier. Revenue of $1.30 billion was in line with estimates. Maximus tops Q4 earnings estimates
  • Positive Sentiment: Management forecast fiscal 2027 revenue of $5.5 billion–$5.7 billion, above the cited $5.4 billion analyst consensus, and free cash flow of $700 million–$800 million while integrating Agile Defense. Maximus forecasts fiscal 2027 free cash flow
  • Negative Sentiment: Quarterly revenue fell 1.3% year over year, and reports noted the shares had slipped below their 200-day moving average, highlighting concerns about near-term momentum. Maximus stock breaks below its 200-day moving average

About Maximus

(Get Free Report)

Maximus, Inc. provides technology-enabled services to government agencies, helping them administer public programs and deliver services to residents. Its work includes managing contact centers, processing applications and eligibility determinations, conducting health assessments, and supporting appeals and other case-management functions. The company serves clients in the United States and internationally, including government agencies in the United Kingdom, Canada and Australia. Its services span health and human services programs as well as federal government operations, with technology and digital services supporting its program work.

Read More

Earnings History for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.